Research progress of liver metastasis in breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HE Hongzhou , SONG Jun ,  WU Bin

Department of Breast Surgery, Affiliated Hospital of Southwest Medical College, Luzhou, Sichuan 646000, P.R.China;

Corresponding?author：

WU Bin, Email: wwbb129@sina.com

Keywords：

breast cancer; liver metastasis; diagnosis; treatment

DOI：

10.7507/1007-9424.201609093

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the mechanism, manifestation, diagnosis and treatment of liver metastasis from breast cancer. Methods The literatures on liver metastasis of breast cancer in PubMed and CNKI Journal Full-text Database were reviewed. Results There are many related studies on the liver metastasis of breast cancer. The diagnosis methods of breast cancer with liver metastasis include CT, B-ultrasound, magnetic resonance imaging, inspection related serological index, pathological biopsy, etc. In the treatment, including systemic treatment and local treatment. However, the transfer mechanism has not been fully clarified, and the clinical manifestations are more prominent. Conclusions Although the liver metastasis of breast cancer incidence is relatively low, but seriously affected the quality of life of patients with breast cancer and prognosis, it is needed to further study and explore the mechanism, provide the basis for the diagnosis and treatment of liver metastasis of breast cancer, achieve long-term prognosis better.

Citation： HE Hongzhou, SONG Jun, WU Bin. Research progress of liver metastasis in breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(7): 905-911. doi: 10.7507/1007-9424.201609093 Copy

1.	Ruiterkamp J, Ernst MF, DE Munck L, et al. Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat, 2011, 128(2): 495-503.
2.	Faraji F, Eissenberg JC. Seed and soil: A conceptual framework of metastasis for clinicians. Mo Med, 2013, 110(4): 302-308.
3.	馬齊襄, 朱曉丹, 胡凱文, 等. 腫瘤轉移的種子與土壤學說新認識. 腫瘤防治研究, 2015, 42(10): 1049-1053.
4.	陳卓, 許新華. 循環腫瘤細胞侵襲轉移的研究進展. 廣東醫學, 2015, 36(13): 2112-2114.
5.	Bork U, Rahbari NN, Sch?lch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer, 2015, 112(8): 1306-1313.
6.	Tsai WS, Chen JS, Shao HJ, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep, 2016, 6: 24517.
7.	Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol, 2012, 19 Suppl 3: S656-S664.
8.	張琳, 呂志棟, 劉相萍, 等. 轉化生長因子-β1 通過誘導上皮-間充質轉化促進乳腺癌細胞侵襲轉移的研究. 中華實驗外科雜志, 2015, 32(5): 979-982.
9.	St Hill CA. Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci (Landmark Ed), 2011, 16: 3233-3251.
10.	Auguste P, Fallavollita L, Wang N, et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol, 2007, 170(5): 1781-1792.
11.	Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol, 2005, 167(3): 749-759.
12.	Yao C, Lin Y, Ye CS, et al. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl). 2007, 120(20): 1766-1772.
13.	周玉麗, 劉瑩瑩, 許金鋒, 等. 趨化因子與乳腺癌關系的研究進展. 廣東醫學, 2015, 36(24): 3880-3883.
14.	Furusato B, Mohamed A, Uhlén M, et al. CXCR4 and cancer. Pathol Int, 2010, 60(7): 497-505.
15.	Hembruff SL, Jokar I, Yang L, et al. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia. 2010, 12(5): 425-433.
16.	Stormes KA, Lemken CA, Lepre JV, et al. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat, 2005, 89(2): 209-212.
17.	Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Letters, 2008, 267(2): 271-285.
18.	Mi Z, Bhattacharya SD, Kim VM, et al. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis, 2011, 32(4): 477-487.
19.	Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene, 2014, 33(38): 4623-4631.
20.	Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol, Immunother, 2014, 63(3): 247-257.
21.	Chao Y, Wu Q, Shepard C, et al. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis, 2012, 29(1): 39-50.
22.	朱海龍. CEA、AFP、CA125、CA15-3、CA19-9 檢測對惡性腫瘤的診斷價值探討. 現代醫藥衛生, 2006, 22(22): 3422-3423.
23.	洪錫田, 王景萍, 張瑞麗. 血清 CA15-3、CA125、CEA、 SF 聯合檢測對乳腺癌的沴斷中的價值. 中國民康醫學, 2007, 19(1): 29-30.
24.	Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg, 2013, 37(6): 1322-1332.
25.	Mariani P, Servois V, De Rycke Y, et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol, 2013, 39(12): 1377-1383.
26.	Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer, 2013, 16(2): 184-192.
27.	Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg, 2010, 62(3): 143-148.
28.	Pentheroudakis G, Fountzilas G. Metastatic breast cancer with liver metastases: a registry analysis, of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat, 2006, 97(3): 237-244.
29.	Er O, Frye DK, Kau SW et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008,14(1): 62-68.
30.	De Santis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252-271.
31.	Wilks S, Puhalla S, O'Shaughnessy J, et al. Phase 2, multicenter, single-arm atudy of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clinical Breast Cancer, 2014, 14(6): 405-412.
32.	Heinemann V, Di Gioia D, Vehling-Kaiser U, et al. A prospective multicenter phase Ⅱ study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing, metastatic breast cancer. Ann Oncol, 2011, 22(3): 603-608.
33.	Chan A, Conte PF, Petruzelka L, et al. Phase Ⅱ study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res, 2013, 33(6): 2657-2664.
34.	Tonyali O, Benekli M, Berk V. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. J Cancer Res Clin Oncol, 2013, 139(6): 981-986.
35.	Tan WW, Allred JB, Salim M, et al. Phase Ⅱ interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer, 2012, 12(2): 81-86.
36.	Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 2012, 366(2): 109-119.
37.	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med , 2011, 365(14): 1273-1283.
38.	Li XP, Meng ZQ, Guo WJ, et al. Treatment for liver metastases from breast cancer: Results and prognostic factors. World J Gastroenterol, 2005, 11(24): 3782-3787.
39.	Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol, 2008, 19(5): 683-690.
40.	Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Bioly Phys, 2007, 69(3): 800-804.
41.	Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with ⁹⁰Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol, 2013, 23(1): 182-189.
42.	Teng W, Liu KW, Lin CC, et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer, 2015, 4(1): 26-38.
43.	Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis, 2011, 15(2): 395-421.
44.	Kang TW, Rhim H. Recent advances in tumor ablation for hepatocellular carcinoma. Liver Cancer, 2015, 4(3): 176-187.
45.	Lencioni R, de Baere T, Martin RC, et al. Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies—A Western perspective. Liver Cancer, 2015, 4(4): 208-214.
46.	Banerjee D, Hernandez SL, Garcia A, et al. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res, 2015, 75(8): 1592-1602.

1. Ruiterkamp J, Ernst MF, DE Munck L, et al. Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat, 2011, 128(2): 495-503.
2. Faraji F, Eissenberg JC. Seed and soil: A conceptual framework of metastasis for clinicians. Mo Med, 2013, 110(4): 302-308.
3. 馬齊襄, 朱曉丹, 胡凱文, 等. 腫瘤轉移的種子與土壤學說新認識. 腫瘤防治研究, 2015, 42(10): 1049-1053.
4. 陳卓, 許新華. 循環腫瘤細胞侵襲轉移的研究進展. 廣東醫學, 2015, 36(13): 2112-2114.
5. Bork U, Rahbari NN, Sch?lch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer, 2015, 112(8): 1306-1313.
6. Tsai WS, Chen JS, Shao HJ, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep, 2016, 6: 24517.
7. Kurashige J, Kamohara H, Watanabe M, et al. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol, 2012, 19 Suppl 3: S656-S664.
8. 張琳, 呂志棟, 劉相萍, 等. 轉化生長因子-β1 通過誘導上皮-間充質轉化促進乳腺癌細胞侵襲轉移的研究. 中華實驗外科雜志, 2015, 32(5): 979-982.
9. St Hill CA. Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci (Landmark Ed), 2011, 16: 3233-3251.
10. Auguste P, Fallavollita L, Wang N, et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol, 2007, 170(5): 1781-1792.
11. Khatib AM, Auguste P, Fallavollita L, et al. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol, 2005, 167(3): 749-759.
12. Yao C, Lin Y, Ye CS, et al. Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin Med J (Engl). 2007, 120(20): 1766-1772.
13. 周玉麗, 劉瑩瑩, 許金鋒, 等. 趨化因子與乳腺癌關系的研究進展. 廣東醫學, 2015, 36(24): 3880-3883.
14. Furusato B, Mohamed A, Uhlén M, et al. CXCR4 and cancer. Pathol Int, 2010, 60(7): 497-505.
15. Hembruff SL, Jokar I, Yang L, et al. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia. 2010, 12(5): 425-433.
16. Stormes KA, Lemken CA, Lepre JV, et al. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat, 2005, 89(2): 209-212.
17. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Letters, 2008, 267(2): 271-285.
18. Mi Z, Bhattacharya SD, Kim VM, et al. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis, 2011, 32(4): 477-487.
19. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene, 2014, 33(38): 4623-4631.
20. Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol, Immunother, 2014, 63(3): 247-257.
21. Chao Y, Wu Q, Shepard C, et al. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis, 2012, 29(1): 39-50.
22. 朱海龍. CEA、AFP、CA125、CA15-3、CA19-9 檢測對惡性腫瘤的診斷價值探討. 現代醫藥衛生, 2006, 22(22): 3422-3423.
23. 洪錫田, 王景萍, 張瑞麗. 血清 CA15-3、CA125、CEA、 SF 聯合檢測對乳腺癌的沴斷中的價值. 中國民康醫學, 2007, 19(1): 29-30.
24. Polistina F, Costantin G, Febbraro A, et al. Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg, 2013, 37(6): 1322-1332.
25. Mariani P, Servois V, De Rycke Y, et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol, 2013, 39(12): 1377-1383.
26. Kostov DV, Kobakov GL, Yankov DV. Prognostic factors related to surgical outcome of liver metastases of breast cancer. J Breast Cancer, 2013, 16(2): 184-192.
27. Rubino A, Doci R, Foteuh JC, et al. Hepatic metastases from breast cancer. Updates Surg, 2010, 62(3): 143-148.
28. Pentheroudakis G, Fountzilas G. Metastatic breast cancer with liver metastases: a registry analysis, of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat, 2006, 97(3): 237-244.
29. Er O, Frye DK, Kau SW et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008,14(1): 62-68.
30. De Santis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252-271.
31. Wilks S, Puhalla S, O'Shaughnessy J, et al. Phase 2, multicenter, single-arm atudy of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clinical Breast Cancer, 2014, 14(6): 405-412.
32. Heinemann V, Di Gioia D, Vehling-Kaiser U, et al. A prospective multicenter phase Ⅱ study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing, metastatic breast cancer. Ann Oncol, 2011, 22(3): 603-608.
33. Chan A, Conte PF, Petruzelka L, et al. Phase Ⅱ study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res, 2013, 33(6): 2657-2664.
34. Tonyali O, Benekli M, Berk V. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. J Cancer Res Clin Oncol, 2013, 139(6): 981-986.
35. Tan WW, Allred JB, Salim M, et al. Phase Ⅱ interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer, 2012, 12(2): 81-86.
36. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 2012, 366(2): 109-119.
37. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med , 2011, 365(14): 1273-1283.
38. Li XP, Meng ZQ, Guo WJ, et al. Treatment for liver metastases from breast cancer: Results and prognostic factors. World J Gastroenterol, 2005, 11(24): 3782-3787.
39. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol, 2008, 19(5): 683-690.
40. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Bioly Phys, 2007, 69(3): 800-804.
41. Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with ⁹⁰Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol, 2013, 23(1): 182-189.
42. Teng W, Liu KW, Lin CC, et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer, 2015, 4(1): 26-38.
43. Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis, 2011, 15(2): 395-421.
44. Kang TW, Rhim H. Recent advances in tumor ablation for hepatocellular carcinoma. Liver Cancer, 2015, 4(3): 176-187.
45. Lencioni R, de Baere T, Martin RC, et al. Image-guided ablation of malignant liver tumors: recommendations for clinical validation of novel thermal and non-thermal technologies—A Western perspective. Liver Cancer, 2015, 4(4): 208-214.
46. Banerjee D, Hernandez SL, Garcia A, et al. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res, 2015, 75(8): 1592-1602.

Previous Article
Research progress of BRCA1 and breast cancer
Next Article
大網膜局灶性扭轉壞死伴腹膜后闌尾炎 1 例報道

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of liver metastasis in breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content